MCRB (Seres Therapeutics) Institutional Ownership: 23.82% (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MCRB Seres Therapeutics Inc MCRB
13 GF Score
Price $4.76
! 5 Warning Signs
View Full Analysis

What is Seres Therapeutics Institutional Ownership?

Seres Therapeutics MCRB -4.80% 13 Institutional Ownership is 23.82% as of Aug. 27, 2026. GuruFocus rates MCRB with a GF Score™ of 13/100. The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Seres Therapeutics's institutional ownership is 23.82%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Seres Therapeutics's Insider Ownership is 11.50%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Seres Therapeutics's Float Percentage Of Total Shares Outstanding is 77.28%.

Seres Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Seres Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seres Therapeutics Institutional Ownership Chart

Seres Therapeutics Historical Data

The historical data trend for Seres Therapeutics can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 8.02 8.21 7.37 7.65 7.73 7.46 7.32 7.13 7.10 7.59
MCRB
13GF Score
Seres Therapeutics Inc MCRB
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seres Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 23.82% mean?
Seres Therapeutics (MCRB) has a Institutional Ownership of 23.82% as of Aug. 27, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Seres Therapeutics and its competitors.
Is Seres Therapeutics' Institutional Ownership too high?
Seres Therapeutics' current Institutional Ownership is 23.82%. Overall, Seres Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Seres Therapeutics' Institutional Ownership compare to IBO and TIL?
Seres Therapeutics' Institutional Ownership of 23.82% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Seres Therapeutics and its competitors. Seres Therapeutics's current Institutional Ownership is 23.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seres Therapeutics stock overvalued right now?
Seres Therapeutics (MCRB) has a current Institutional Ownership of 23.82%. The current Institutional Ownership is 23.82%. Seres Therapeutics' overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Seres Therapeutics (MCRB), the current Institutional Ownership is 23.82% as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seres Therapeutics Business Description

Other Exchanges 1S90:Germany
Address 101 Cambridgepark Drive, Cambridge, MA, USA, 02140
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
13GF Score

Get the complete analysis for MCRB

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.76
Price